



MEDTECS INTERNATIONAL CORPORATION LIMITED
(Incorporated in Bermuda)

MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)

1. INTRODUCTION

The Board of Directors (the "**Board**") of Medtecs International Corporation Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the Company's announcements dated 3 December 2024, 27 December 2024, 17 January 2025, 24 January 2025, 27 February 2025, 27 March 2025, 25 April 2025, 8 May 2025, 28 May 2025, 30 June 2025, 25 July 2025, 25 August 2025, 24 September 2025, 29 October 2025, 24 November 2025, and 29 December (the "**Announcements**") in relation to, among others, the Winding Up Application and the Court Order in respect of Resilient Medical.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the meanings ascribed to them in the Announcements.

2. MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)

Pursuant to Rule 704(22) of the Catalist Rules, the Board wishes to update shareholders that the liquidator has informed the Company that the relevant application in relation to the liquidation of Resilient Medical was filed with the High Court of Singapore on 22 January 2026, and that the hearing date has been fixed on 3 February 2026 at 10:00 a.m..

The Group is currently awaiting the outcome of the hearing and the issuance of the final court order in relation to the dissolution of Resilient Medical.

The Company will provide further updates as and when there are material developments in respect of the liquidation proceedings.

3. FINANCIAL IMPACT

Based on the information currently available to it and save as disclosed in this announcement, the Board has assessed that the winding-up of Resilient Medical and the transfer of the entire issued share capital in RMKH SG to the Company pursuant to the dividend in specie declared by Resilient Medical does not have a material impact on the net tangible assets per share or the earnings per share of the Company for the current financial year ending 31 December 2026.

The Company will also release further announcements to update its shareholders as and when there are material developments in relation to the winding up of Resilient Medical in between the monthly updates.

4. CAUTION IN TRADING

Shareholders and potential investors of the Company are advised to read this announcement and any further announcements made by the Company carefully. Shareholders and potential investors of the Company are advised to refrain from taking

any action with respect to their securities in the Company which may be prejudicial to their interests, and to exercise caution when dealing in the securities of the Company. Shareholders and potential investors of the Company should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

BY ORDER OF THE BOARD

Clement Yang Ker-Cheng
Chairman – Executive Director
29 January 2026

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Foo Jien Jieng, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.